| 14.02 -0.25 (-1.75%) | 05-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 22.37 | 1-year : | 26.11 |
| Resists | First : | 19.15 | Second : | 22.36 |
| Pivot price | 15.57  |
|||
| Supports | First : | 13.96 | Second : | 11.62 |
| MAs | MA(5) : | 14.4 |
MA(20) : | 16.59 |
| MA(100) : | 18.78 |
MA(250) : | 13.81 |
|
| MACD | MACD : | -1.6 |
Signal : | -1.5 |
| %K %D | K(14,3) : | 2.8 |
D(3) : | 5.9 |
| RSI | RSI(14): 31 |
|||
| 52-week | High : | 31 | Low : | 4.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PTN ] has closed above bottom band by 30.5%. Bollinger Bands are 35.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 14.52 - 14.6 | 14.6 - 14.69 |
| Low: | 13.8 - 13.9 | 13.9 - 13.99 |
| Close: | 13.87 - 14.01 | 14.01 - 14.16 |
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
Fri, 29 May 2026
Palatin Technologies, Inc. Earnings and Revenue – NASDAQ:PTN - TradingView
Fri, 29 May 2026
Palatin Technologies, Inc. Financial Statements – NASDAQ:PTN - TradingView
Fri, 29 May 2026
Equity in earnings of Palatin Technologies, Inc. – NASDAQ:PTN - TradingView
Fri, 29 May 2026
Palatin Technologies, Inc. Income Statement – NASDAQ:PTN - TradingView
Thu, 28 May 2026
Palatin Technologies (PTN) files Form 25 to withdraw NYSE American listing - Stock Titan
Fri, 22 May 2026
PTN Technical Analysis | Trend, Signals & Chart Patterns | PALATIN TECHNOLOGIES INC (NYSEARCA:PTN) - ChartMill
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|